Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Microbix Biosystems Inc > New Press Release - Microbix Reports Continued Strong Results for Q3 Fiscal 2024
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(121)
•••
Comment by prophetoffactzon Aug 15, 2024 8:19am
70 Views
Post# 36180133

RE:RE:RE:New Press Release - Microbix Reports Continued Strong Results for Q3 Fiscal 2024

RE:RE:RE:New Press Release - Microbix Reports Continued Strong Results for Q3 Fiscal 2024I think they said in the conference call that they expect 20-40% growth next fiscal year. Given the margins a few years of growth like that at Kinlytic advances could be golden.

lscfa wrote:

 

Antigen + QAP

Qtr ending 

Antigen

QAP

4,946,122

Jun 24

3,276,469

1,669,653

5,511,058

Mar 24

4,111,462

1,399,596

4,201,913

Dec 23

1,953,677

2,248,236

4,172,410

Sep 23

2,977,179

1,195,231

4,065,426

Jun 23

2,608,521

1,456,905

4,106,414

Mar 23

3,004,730

1,101,684

2,337,310

Dec 22

1,003,807

1,333,503

4,231,801

Sept 22

2,629,901

1,601,900

3,589,517

Jun 22

2,283,621

1,305,896

2,926,352

Mar 22

1,607,970

1,318,382

2,915,567

Dec 21

1,766,416

1,149,151

3,216,406

Sep 21

2,020,861

1,195,545

3,450,586

Jun 21

2,398,969

1,051,617

4,019,451

Mar 21

2,524,363

1,495,088

3,100,250

Dec 20

2,137,829

962,421

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities